Table 2.
Adjusted hazard ratios and 95% confidence intervals of selected benign tumors comparing myotonic dystrophy type I (DM1)‐affected with matched DM1‐free controls.
| Tumor/Site | Tumor frequency1 n (%) | HR2 | 95% CI | P‐value | ||
|---|---|---|---|---|---|---|
| DM1 | DM1‐free | |||||
| Skin | 85 (9.2%) | 623 (4.8%) | ||||
| Lipoma | 0.9 | 0.45 | 1.86 | 0.81 | ||
| Other skin tumors3 | 1.4 | 1.08 | 1.95 | 0.01 | ||
| Pilomatricoma | – | – | – | <0.0016 | ||
| Female genital | 14 (1.5%) | 82 (0.6%) | ||||
| Uterine fibroids | 2.7 | 1.22 | 5.88 | 0.01 | ||
| Uterine polyps | 9.6 | 1.20 | 77.49 | 0.03 | ||
| Cervical polyps | 0.4 | 0.05 | 2.96 | 0.36 | ||
| Endocrine | 9 (1.0%) | 19 (0.2%) | ||||
| Pituitary tumors4 | 11.0 | 0.49 | 250.14 | 0.13 | ||
| Thyroid nodules/cysts | 10.4 | 3.91 | 27.52 | <0.001 | ||
| Digestive | 10 (1.1%) | 42 (0.3%) | ||||
| Colorectal polyps | 4.3 | 1.76 | 10.41 | 0.001 | ||
| Other digestive tumors | – | – | – | >0.996 | ||
| Brain & nervous system5 | 7 (0.8%) | 11 (0.1%) | 8.4 | 2.48 | 28.47 | <0.001 |
| Other tumors | 13 (1.4%) | 67 (0.5%) | ||||
| Salivary glands | – | – | – | <0.0016 | ||
| Breast fibroadenoma | – | – | – | >0.996 | ||
| Other/Unknown7 | 1.4 | 0.67 | 3.09 | 0.35 | ||
In accordance with CPRD policy which prohibits the reporting of cells with fewer than five events, frequencies were reported by system, where applicable.
Baseline hazards were stratified on the matched sets and models were adjusted for number of healthcare care encounters.
Skin tumors included nevi, dermatofibromas, papillomas, moles, and other benign neoplasm of the skin.
In DM1, all pituitary tumors were adenomas; in controls, pituitary tumors included adenomas and craniopharyngiomas.
Brain & nervous system tumors included meningiomas, neuromas, neurofibromas, and other benign neoplasms of the brain & nervous system.
Obtained from Fisher's Exact test due to sparse or zero events in at least one group.
Other/unknown tumors include tumors of the bone & connective tissue, lip/oral cavity/pharynx, lymphatic/hematopoietic, respiratory, and unspecified sites (total n = 75).